Cargando…
Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation
Reports about cases of anaphylaxis to mRNA vaccines have created anxiety in the community and could increase vaccine hesitancy in the population. There are no standardized protocols for allergy testing to mRNA vaccines. PEG is currently the only excipient in both vaccines with recognized allergenic...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080508/ https://www.ncbi.nlm.nih.gov/pubmed/33932618 http://dx.doi.org/10.1016/j.clim.2021.108748 |
_version_ | 1783685441551073280 |
---|---|
author | Erdeljic Turk, Viktorija |
author_facet | Erdeljic Turk, Viktorija |
author_sort | Erdeljic Turk, Viktorija |
collection | PubMed |
description | Reports about cases of anaphylaxis to mRNA vaccines have created anxiety in the community and could increase vaccine hesitancy in the population. There are no standardized protocols for allergy testing to mRNA vaccines. PEG is currently the only excipient in both vaccines with recognized allergenic potential. Allergy to PEG has been reported with increasing frequency over recent years, often in patients who had repeated systemic allergic reactions/anaphylaxis to several classes of drugs before diagnosis. Proposed protocols are based on current knowledge about potential mechanisms of anaphylaxis associated with the mRNA vaccines, and the assumption that polyethylene glycol (PEG) is the most likely culprit. Allergy testing to PEGs and mRNA vaccines is complex and carries the risk of anaphylaxis and should be conducted in a specialist drug allergy center. Appropriate PEG-free emergency medical treatment and supervision should be readily available. |
format | Online Article Text |
id | pubmed-8080508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80805082021-04-29 Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation Erdeljic Turk, Viktorija Clin Immunol Article Reports about cases of anaphylaxis to mRNA vaccines have created anxiety in the community and could increase vaccine hesitancy in the population. There are no standardized protocols for allergy testing to mRNA vaccines. PEG is currently the only excipient in both vaccines with recognized allergenic potential. Allergy to PEG has been reported with increasing frequency over recent years, often in patients who had repeated systemic allergic reactions/anaphylaxis to several classes of drugs before diagnosis. Proposed protocols are based on current knowledge about potential mechanisms of anaphylaxis associated with the mRNA vaccines, and the assumption that polyethylene glycol (PEG) is the most likely culprit. Allergy testing to PEGs and mRNA vaccines is complex and carries the risk of anaphylaxis and should be conducted in a specialist drug allergy center. Appropriate PEG-free emergency medical treatment and supervision should be readily available. Elsevier Inc. 2021-06 2021-04-28 /pmc/articles/PMC8080508/ /pubmed/33932618 http://dx.doi.org/10.1016/j.clim.2021.108748 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Erdeljic Turk, Viktorija Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation |
title | Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation |
title_full | Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation |
title_fullStr | Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation |
title_full_unstemmed | Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation |
title_short | Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation |
title_sort | anaphylaxis associated with the mrna covid-19 vaccines: approach to allergy investigation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080508/ https://www.ncbi.nlm.nih.gov/pubmed/33932618 http://dx.doi.org/10.1016/j.clim.2021.108748 |
work_keys_str_mv | AT erdeljicturkviktorija anaphylaxisassociatedwiththemrnacovid19vaccinesapproachtoallergyinvestigation |